WASHINGTON - The Senate Committee on Finance will hold two days of hearings next week to consider how fraud, waste and abuse harm the Medicaid program.
The first hearing is scheduled for Tuesday, June 28, at 10 a.m. in Room 216 of the HartSenate Office Building. The committee will consider differences between Medicaid andMedicare oversight and how the complexity of the Medicaid program makes it difficult tooversee and account for misuse. The committee will also review various ways the states accessfederal Medicaid dollars.
The following witnesses are scheduled to testify on Tuesday.
Panel 1 -
Mr. Daniel Levinson, Inspector General Office of the Inspector General, U.S. Department of Health and Human Services Washington, DC
Ms. Leslie Aronovitz, Director, Health Care Government Accountability Office Chicago, Illinois
Mr. James W. Moorman, President and CEO Taxpayers Against Fraud Washington, DC
Mr. Nicholas Messuri, President, National Association of Medicaid Fraud Control Units Assistant Attorney General, Director Medicaid Fraud Control Unit Bureau Chief, Business & Labor Protection Bureau Massachusetts Office of the Attorney General Boston, Massachusetts
Mr. Tim Westmoreland, Research Professor Georgetown University Washington, DC
Panel 2 -
Ms. Kathryn Allen, Director, Health Care Government Accountability Office Washington, DC
Mr. Dennis Smith, Director, Center for Medicaid and State Operations Center for Medicare and Medicaid Services, U.S. Department of Health and Human Services Washington, DC
Ms. Barbara Edwards, Medicaid Director Office of Ohio Health Plans Columbus, Ohio
Mr. George Reeb, Assistant Inspector General for the Centers for Medicare & Medicaid Audits Office of the Inspector General, U.S. Department of Health and Human Services Washington, DC
Mr. Chuck Milligan, Executive Director Center for Health Program Development and Management University of Maryland, Baltimore County Baltimore, Maryland
The second hearing is scheduled for Wednesday, June 29, at 10 a.m. in room 216 of theHart Senate Office Building. The committee will review Medicaid’s pricing and paymentpolicies for prescription drugs and the practice of transferring assets by older individuals relyingon Medicaid for long-term care needs.
The following witnesses are scheduled to testify on Wednesday.
Panel 1 -
a pharmaceutical industry whistleblower
Mr. Timothy Coleman, Associate Deputy Attorney General U.S. Department of Justice Washington, DC
Mr. Robert Vito, Regional Inspector General for Evaluations and Inspections Office of the Inspector General, U.S. Department of Health and Human Services Philadelphia, Pennsylvania
Mr. Patrick O’Connell, Assistant Attorney General Office of the Attorney General, State of Texas Austin, Texas
Mr. Billy Tauzin, CEO (Invited)
Pharmaceutical Research Manufacturers of America Washington, DC
Panel 2 -
Mr. Daniel O’Brien, Senior Vice President Erickson Retirement Communities Baltimore, Maryland
Ms. Ruth Pundt, Resident Erickson Retirement Communities Parkville, Maryland
Ms. Julie Stone, Specialist in Social Legislation Congressional Research Service Washington, DC
Mr. Paul Pickerell, Manager, Financial Recoveries Division Oregon Department of Human Services Eugene, Oregon
Ms. Joyce Ruddock, Vice President, Long Term Care Division MetLife Insurance on behalf of American Council of Life Insurers Westport, Connecticut
Dr. Judy Feder, Dean, Public Policy Institute Georgetown University Washington, DC.
-30-
Source: Ranking Member’s News
